Dental caries in permanent teeth · Children and adolescents (<18 years) living with HIV (CLWH)
Among HIV+ children, HAART was associated with a significantly higher DMFT index than no HAART in case-control studies (MD 2.02, 95% CI 1.24 to 2.80; ungraded).
1 finding from 1 review
Caries in primary teeth: dmft (3 years) · Children and adolescents (<18 years) living with HIV (CLWH)
Among HIV+ children, HAART versus no HAART showed no significant difference in the dmft index in case-control studies (MD 0.66, 95% CI -0.26 to 1.58; ungraded).
1 finding from 1 review
Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) showed no clear difference in total mortality compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 1.08 [0.69, 1.70]
1 study
GRADE not reported
Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) showed no clear difference in locoregional control compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 0.78 [0.55, 1.11]
1 study
GRADE not reported
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with inflammatory bowel disease
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
Restoration survival · Children with occlusoproximal caries in primary teeth
Multiple reviews reported similar restoration survival for ART versus conventional restorations in occlusoproximal cavities (ungraded).
1 finding from 1 review
Length of hospital stay · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital costs · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with severe acute pancreatitis
High‐volume continuous veno‐venous hemofiltration (CVVH) showed no clear difference in all‐cause mortality compared with standard CVVH (low certainty).
1 finding from 1 review
Adverse events · adults with severe acute pancreatitis
It is very uncertain whether high‐volume continuous veno‐venous hemofiltration (CVVH) changes adverse events compared with standard CVVH (very low certainty).
1 finding from 1 review
Duration of ICU stay · adults with severe acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with standard‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with standard‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review